Provide 100 g/ton chlortetracycline, 100 g/ton sulfathiazole, and 50 g/ton of penicillin by thoroughly mixing 2.5 lb (1.14 kg) of AureoZol 500 Granular into each ton (907.2 kg) of complete swine feed for the following indications.
Aureomycin® chlortetracycline,
sulfathiazole and penicillin
Type A Medicated Article
Chlortetracycline calcium complex equivalent to
Chlortetracycline HCl ............................................................................... 40 g / lb
Sulfathiazole .................................................................................. 8.8% (40 g / lb)
Penicillin (from procaine penicillin) .......................................................... 20 g / lb
Dried Streptomyces aureofaciens Fermentation Product and calcium sulfate.
For use in the manufacture of medicated swine feeds. For animal use only.
Provide 100 g/ton chlortetracycline, 100 g/ton sulfathiazole, and 50 g/ton of penicillin by thoroughly mixing 2.5 lb (1.14 kg) of AureoZol 500 Granular into each ton (907.2 kg) of complete swine feed for the following indications.
For Use in Swine Feeds as Specified Below:
Administer to swine in a complete medicated feed for reduction of the incidence of cervical abscesses; treatment of bacterial enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery); maintenance of weight gains in the presence of atrophic rhinitis; increased rate of weight gain and improved feed efficiency from 10 pounds of body weight to 6 weeks postweaning. For swine raised in confinement (dry-lot) or on limited pasture.
Administer to swine in a complete medicated feed for reduction of the incidence of cervical abscesses; treatment of bacterial enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery); maintenance of weight gains in the presence of atrophic rhinitis; increased rate of weight gain from 6 to 16 weeks post-weaning. For swine raised in confinement (dry-lot) or on limited pasture.
In order to achieve the desired performance results, feed as the sole ration.
Withdraw 7 days prior to slaughter.
Note: Manufacture of Type B or C feeds from this product requires a Medicated Feed License Application approved by FDA.
ANADA #200-167, Approved by FDA
Restricted Drug (California) - Use only as directed.
Not for human use.
Marketed by
Alpharma Inc.
Bridgewater, New Jersey 08807
Net wt 50 LB (22.68 kg)
Made in USA
Trademarks
registered by
Alpharma Inc.
700339 0909
AureoZol®
Granular 500
ALPHARMA
Aureomycin® chlortetracycline,
sulfathiazole and penicillin
Type A Medicated Article
See mixing directions, claims, cautions
and warnings on back
Net wt 50 LB (22.68 kg)
ALPHARMA®
AureoZol®
Granular 500
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Chlortetracycline Calcium | ACTIVE INGREDIENT | NR4B2SX17S | 1 | |
| Penicillin G | ACTIVE INGREDIENT | Q42T66VG0C | 1 | |
| Procaine | ACTIVE INGREDIENT | 4Z8Y51M438 | 1 | |
| Sulfathiazole | ACTIVE INGREDIENT | Y7FKS2XWQH | 1 | |
| Chlortetracycline | ACTIVE MOIETY | WCK1KIQ23Q | 1 | |
| Penicillin G | ACTIVE MOIETY | Q42T66VG0C | 1 | |
| Procaine | ACTIVE MOIETY | 4Z8Y51M438 | 1 | |
| Sulfathiazole | ACTIVE MOIETY | Y7FKS2XWQH | 1 | |
| Calcium Sulfate | INACTIVE INGREDIENT | WAT0DDB505 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 46573-022 | 46573-022-00 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Chlortetracycline Calcium | NR4B2SX17S | ACTIM |
| Sulfathiazole | Y7FKS2XWQH | ACTIB |
| Penicillin G | Q42T66VG0C | ACTIM |
| Procaine | 4Z8Y51M438 | ACTIM |
| Calcium Sulfate | WAT0DDB505 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | CAPSULE / ORAL | 141.5 mg | ||
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | TABLET, COATED / ORAL | 170 mg | ||
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | TABLET / ORAL | 2734 mg | ||
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | TABLET, DELAYED RELEASE / ORAL | 127 mg | ||
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | TABLET, EXTENDED RELEASE / ORAL | 235 mg | ||
| Calcium Sulfate | CALCIUM SULFATE | WAT0DDB505 | CAPSULE, EXTENDED RELEASE / ORAL | 1.66 mg |
Adverse event summaries are temporarily unavailable. Other product information remains available.